Advances in imaging in Parkinson's disease
- PMID: 22014434
- DOI: 10.1016/S1474-4422(11)70214-9
Advances in imaging in Parkinson's disease
Abstract
Advances in imaging have made it possible to detect functional and, increasingly, structural changes in Parkinson's disease. Although imaging is not yet routinely used for diagnosis, such an application is becoming increasingly feasible. Of potentially greater interest, however, is the use of imaging as a biomarker to detect premotor disease and disease progression. Imaging also provides insights into complications of Parkinson's disease and its long-term treatment, and the role of dopamine in the normal brain. Furthermore, these techniques can be applied to animal models, to help validate these models and allow their use in the study of potential disease-modifying therapies.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Biomarkers for trials of neuroprotection in Parkinson's disease.Mov Disord. 2013 Jan;28(1):71-85. doi: 10.1002/mds.25065. Epub 2012 Aug 24. Mov Disord. 2013. PMID: 22927101 Review.
-
Neuroimaging in Parkinson's disease: from pathology to diagnosis.Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S55-9. doi: 10.1016/S1353-8020(11)70019-0. Parkinsonism Relat Disord. 2012. PMID: 22166455 Review.
-
Imaging insights into basal ganglia function, Parkinson's disease, and dystonia.Lancet. 2014 Aug 9;384(9942):532-44. doi: 10.1016/S0140-6736(14)60041-6. Epub 2014 Jun 18. Lancet. 2014. PMID: 24954673 Free PMC article. Review.
-
Assessment of the progression of Parkinson's disease: a metabolic network approach.Lancet Neurol. 2007 Oct;6(10):926-32. doi: 10.1016/S1474-4422(07)70245-4. Lancet Neurol. 2007. PMID: 17884682 Free PMC article. Review.
-
Neuroimaging: current role in detecting pre-motor Parkinson's disease.Mov Disord. 2012 Apr 15;27(5):634-43. doi: 10.1002/mds.24976. Mov Disord. 2012. PMID: 22508281 Review.
Cited by
-
First-in-human study of D6-[18F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [18F]FP-(+)-DTBZ (AV-133).EJNMMI Radiopharm Chem. 2024 Oct 16;9(1):71. doi: 10.1186/s41181-024-00301-y. EJNMMI Radiopharm Chem. 2024. PMID: 39412702 Free PMC article.
-
Thai national guideline for nuclear medicine investigation in movement disorders: Nuclear medicine society of Thailand, the neurological society of Thailand, and Thai medical physicist society collaboration.Asia Ocean J Nucl Med Biol. 2024;12(2):86-107. doi: 10.22038/AOJNMB.2023.75619.1531. Asia Ocean J Nucl Med Biol. 2024. PMID: 39050239 Free PMC article.
-
Clinical biomarkers for Lewy body diseases.Cell Biosci. 2023 Nov 14;13(1):209. doi: 10.1186/s13578-023-01152-x. Cell Biosci. 2023. PMID: 37964309 Free PMC article. Review.
-
An interpretable multiparametric radiomics model of basal ganglia to predict dementia conversion in Parkinson's disease.NPJ Parkinsons Dis. 2023 Aug 30;9(1):127. doi: 10.1038/s41531-023-00566-1. NPJ Parkinsons Dis. 2023. PMID: 37648733 Free PMC article.
-
Utility of 18F FDG-PET in Parkinsonism in an African population.eNeurologicalSci. 2022 Mar 31;27:100399. doi: 10.1016/j.ensci.2022.100399. eCollection 2022 Jun. eNeurologicalSci. 2022. PMID: 35434388 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
